The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at ...

Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance ...

New Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs, and Program Leadership Phio ...

Phase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, ...

The Safety Monitoring Committee concluded its review of the trial, reporting no serious adverse events or dose-limiting toxicities across all five dose escalation cohorts. Notably, the highest dose ...

Following completion of the treatment period through excision of the tumor, safety data from the initial cohort of three subjects in the Phase 1 trial was evaluated by the DMC. The safety data review ...

MARLBOROUGH, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make ...

Marlborough biopharma Phio Pharmaceuticals is ushering in a new strategic plan seeking to reposition the company from pure discovery research to full development, utilizing clinical trials. As part of ...

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in ...

Phio Pharmaceuticals' stock surged on Monday with a session volume of around 200 million. Phase 1b trial results: 2 patients achieved a complete response with 100% tumor clearance; no dose-limiting ...